{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-094341","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.911812+00:00","generated_at":"2026-05-31T10:30:24.245281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProKidney reports Q2 net loss $38.5M, cash $431.5M, restarts Phase 3 trials","bullets":["Interim Phase 2 REGEN-007 data show kidney function stabilization for 18 months in diabetes/advanced CKD patients.","Manufacturing restarted; QP Declaration of Equivalence received in July; PROACT 1 and 2 trials resumed.","Closed $140M upsized equity offering in June, extending cash runway into mid-2026.","Cash & equivalents $431.5M at June 30, 2024 (vs $363.0M Dec 31, 2023).","R&D expenses $29.4M (Q2 2024) vs $26.4M (Q2 2023); net loss $38.5M vs $34.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-094341","json":"https://secwatch.observer/filing/0000950170-24-094341.json","markdown":"https://secwatch.observer/filing/0000950170-24-094341.md","text":"https://secwatch.observer/filing/0000950170-24-094341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024094341/0000950170-24-094341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024094341/prok-20240809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:30:24.245281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}